Regarding the article Optimal use of smokingcessation pharmacotherapy by Colin Mendelsohn,1 it should be noted that, due to nitrosamine contamination, varenicline was recalled by its Australian sponsor in 2021, and the date of return is estimated to be in 2023. There are alternative Section 19A approved products available but, as of the time of writing, these are not listed on the Pharmaceutical Benefits Scheme, leaving patients with a significant out‑of‑pocket cost. Section 19A products are also by definition temporary supply products and liable to becoming unavailable themselves.
Nick Standen Pharmacist lecturer, LaTrobe Rural Health School, Bendigo, Vic.
Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer. This website uses cookies. Read our privacy policy.